AGP Picks
View all

Healthy Living Maine: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Maine.

Press releases published on October 22, 2026

Synchrocare Announces Franchise Opportunities Across Maine to Support Healthcare Providers Statewide
Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering
Das KFSH erweitert seine Kapazitäten für die komplexe Versorgung durch eine Neugestaltung des Behandlungsablaufs für Notfallpatienten
Le KFSH renforce ses capacités de prise en charge des soins complexes en repensant le parcours des patients aux urgences
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Delta Dental Foundation of North Carolina Commits $1 Million  to Expand Oral Health Access Statewide
Park Family & Cosmetic Dentistry Named Best Cosmetic Dentistry Practice in Naples, FL
FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
VisCardia Announces Publication of RECOVER-HF Pilot Trial in JACC: Heart Failure
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Health Catalyst to Announce Third Quarter 2026 Operating Results and Host Conference Call on Thursday, November 5, 2026

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthy Living Maine

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.